Fatigue News and Research

RSS

ATA recognizes 4th Annual World Thyroid Day

The American Thyroid Association, in cooperation with sister international thyroid societies, the European Thyroid Association, the Asia & Oceania Thyroid Association, and the Latin American Thyroid Society, recognizes the 4th Annual World Thyroid Day, May 25, 2011.

26 May 2011

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

New cancer study finds benefit in old therapy

Cancer patients who used a 5,000-year-old combination of gentle exercise and meditation experienced significantly higher wellbeing levels, improved cognitive functioning and less inflammation compared to a control group, new University of Sydney research has found.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Free, online tool to track exercise-induced asthma

Running into breathing problems when you exercise? You may have exercise-induced bronchoconstriction (EIB), commonly referred to as exercise-induced asthma. The American College of Allergy, Asthma and Immunology (ACAAI) has developed a free, easy-to-use online tool to track your symptoms: MyEIBJournal.org.

20 May 2011

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

AstraZeneca announced today encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) who had received maintenance treatment with the investigational drug olaparib, after the completion of chemotherapy.

19 May 2011

Aspirin, simvastatin not effective in combating pulmonary artery hypertension

Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health (NIH)-funded study conducted at four U.S. medical centers. This was the first NIH-funded randomized clinical trial (RCT) in PAH.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

Childhood physical abuse linked to elevated rates of chronic fatigue syndrome among women

Childhood physical abuse is associated with significantly elevated rates of functional somatic syndromes such as chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities among women, according to new findings by University of Toronto researchers.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Imaginary bugs flummox dermatologists

It is known that some people have the “delusional bug syndrome” and are convinced that bugs, worms, germs, or other creepy crawlers are infesting their skin and often see skin doctor after skin doctor to find out what is causing the infestation. Often, patients bring in samples of the insect and request a skin biopsy.

17 May 2011

Loyola earns Joint Commission certification for heart pump therapy

Loyola University Hospital has been certified by the Joint Commission to begin implanting heart pumps known as left ventricular assist devices (LVADs) as permanent therapy for advanced heart failure.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment.

16 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Using geriatric mice, a Johns Hopkins research team has shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.

12 May 2011

Fatigue News and Research

ATA recognizes 4th Annual World Thyroid Day

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

New cancer study finds benefit in old therapy

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Vertex receives FDA approval for INCIVEK to treat hepatitis C

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Free, online tool to track exercise-induced asthma

AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer

Aspirin, simvastatin not effective in combating pulmonary artery hypertension

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

Childhood physical abuse linked to elevated rates of chronic fatigue syndrome among women

FDA nod for hepatitis C drug

Imaginary bugs flummox dermatologists

Loyola earns Joint Commission certification for heart pump therapy

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News